Matinas BioPharma (NYSEAMERICAN:MTNB) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a research report released on Wednesday, June 26th, BenzingaRatingsTable reports. The firm issued a buy rating and a $4.00 target price on the stock.

Several other equities research analysts have also recently issued reports on the company. Maxim Group set a $25.00 target price on Aridis Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, May 16th. BTIG Research began coverage on Matinas BioPharma in a research note on Friday, May 17th. They set a buy rating and a $5.00 target price for the company. Finally, Zacks Investment Research cut Horiba from a hold rating to a sell rating in a research note on Wednesday, May 22nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Matinas BioPharma has an average rating of Buy and a consensus target price of $4.00.

Shares of MTNB stock traded up $0.01 during mid-day trading on Wednesday, reaching $0.74. The stock had a trading volume of 1,111,000 shares, compared to its average volume of 965,150. Matinas BioPharma has a 1-year low of $0.34 and a 1-year high of $1.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01).

In related news, Director Adam K. Stern bought 80,000 shares of Matinas BioPharma stock in a transaction that occurred on Friday, May 31st. The shares were purchased at an average price of $0.94 per share, with a total value of $75,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have bought a total of 187,487 shares of company stock worth $167,290 in the last three months.

Several institutional investors have recently made changes to their positions in the company. Vivo Capital LLC acquired a new position in Matinas BioPharma in the first quarter worth approximately $7,432,000. IPG Investment Advisors LLC boosted its stake in Matinas BioPharma by 54.5% in the 1st quarter. IPG Investment Advisors LLC now owns 42,500 shares of the company’s stock worth $46,000 after purchasing an additional 15,000 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Matinas BioPharma during the 1st quarter valued at $1,867,000. Brighton Jones LLC acquired a new stake in shares of Matinas BioPharma during the 1st quarter valued at $55,000. Finally, Virtu Financial LLC boosted its stake in shares of Matinas BioPharma by 80.0% during the 1st quarter. Virtu Financial LLC now owns 116,636 shares of the company’s stock valued at $127,000 after buying an additional 51,853 shares during the period.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Further Reading: What is a Stop Order?

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.